Humanigen Inc. (HGEN) Stock Trends Higher Following Upcoming Partnership with Clinigen Group

Humanigen Inc. (HGEN) stock prices were up by 6.35% as of the market closing on October 7th 2021. This brought the price per share up to USD$6.36 at the end of the trading day. Subsequent premarket fluctuations have seen the stock surge by 4.24%, bringing it up to USD$6.63.

Collaboration with HGEN Stock

October 8th, 2021 saw HGEN stock announce having entered into an arrangement with Clinigen Group PLC. The partnership with the global pharmaceutical Services and Products company will facilitate the implementation of a Managed Access Program for lenzilumab. The program is called LenzMAP and will enable access to lenzilumab on a case by case basis for hospitalized patients with Covid-19. These will be cases where the treating physician believes there to be no suitable alternatives, where regulations allow. The program will be available in 16 European countries. Across these 16 countries, there have been more than 20 million cases of Covid-19 being reported. Lenzilumab is still in its investigational phase, resulting in it currently not being authorized or approved in any country.

Synergistic Collaboration

HGEN stock is continuing to collaborate with Clinigen in a partnership designed to provide access to lenzilumab on a patient by patient basis in various European countries. The company is continuing with its pursuit of a Marketing Authorization Application for the treatment and is currently waiting for the associated review by the European Medicines Agency. A decision regarding conditional marketing authorization will also be made. Meanwhile, the Managed Access Program will allow the company to respond positively to requests for access from healthcare professionals to treat hospitalized patients, where allowed by the local regulatory authorities.

Scope of HGEN Stock’s Partnership

As per the agreement, Clinigen will manage critical components of the program, including regulatory oversight, logistics, and access management. The partnership will see HGEN stock and Clinigen combine resources to offer the lenzilumab treatment option to help address a substantial unmet need for hospitalized patients with Covid-19 across Europe. The agreement serves to underline the partnering company’s strength in collaborating with biotechnology companies. These partnerships aim to provide services that enables quicker and broader access to critical medicines.

Future Outlook for HGEN Stock

HGEN stock is poised to capitalize on the expanded scope of opportunities afforded to the company by its partnership with Clinigen. The company is keen to maintain its recent trajectory of success in a bit to usher un unprecedented growth. Current and potential investors are hopeful that management will be able to effectively leverage the resources at its disposal. This is hoped to facilitate significant and sustained increases in shareholder value.